卡斯波金在重症中国儿童中的种群药动力学:一项前性观察性研究
Nuo Xu1, Yufei Shi1,2, Gehang Ju3
1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Antimicrobial agents and chemotherapy
|December 30, 2025
概括
这项研究澄清了在儿科重症监护室 (PICU) 中的重症儿童的卡斯波金剂量. 目前的治疗方案得到了支持,并对身体表面积 (BSA) 剂量进行了具体建议.
科学领域:
- 药理学和制药科学 药理学和制药科学
- 关键护理医学 关键护理医学
- 儿童传染病 儿童传染病
背景情况:
- 在儿科重症监护病房 (PICU) 侵袭性真菌感染中,卡斯波金至关重要.
- 在重症儿童中药理动力学数据和剂量证据有限.
- 了解卡斯波金的药理动力学对于优化这种脆弱人群的治疗至关重要.
研究的目的:
- 在重症儿科患者中描述卡斯波金的种群药动力学.
- 在这个队列中确定卡斯波金的最佳剂量策略.
- 为了评估体外膜氧化 (ECMO) 对菌素暴露的影响.
主要方法:
- 未来临床研究涉及PICU的儿科患者.
- 群体药理动力学分析使用二分区模型与全米缩放.
- 蒙特卡洛模拟用于评估药物动力学/药物动力学目标和剂量策略.
主要成果:
- 一个带有BSA全米缩放的两部分模型描述了caspofungin的药理动力学.
- 体外膜氧化 (ECMO) 增加了中央分布体积,但没有显著改变AUC.
- 模拟支持当前的剂量方案,建议BSA≥1.4 m2的固定维持剂量和BSA<1.4 m2的BSA基剂量.
结论:
- 这项研究证实了中国重症儿科重症监护病房患者推的卡斯波金剂量方案.
- 考虑到BSA和ECMO的支持,目前的剂量策略似乎是适当的.
- 为了验证这些发现,需要对更大的ECMO种群进行进一步的研究.
相关概念视频
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
209
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
209
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133